LaViolette Sees Opportunities Behind The Risks In Down Economy
This article was originally published in The Gray Sheet
Executive Summary
Paul LaViolette has a unique perspective on the device industry, having worked with some of the biggest and most established firms as well as brand new start-ups
You may also be interested in...
People In Brief
LaViolette ventures from Boston Sci: Former Boston Scientific Chief Operating Officer Paul LaViolette will join venture capital firm SV Life Sciences next month as a venture partner in the company's Boston office and medical technology segment. LaViolette relinquished the COO position July 1 as part of an executive restructuring at Boston Scientific (1"The Gray Sheet" June 9, 2008, p. 8). LaViolette will leave the device firm outright at the end of the year after six months as a company advisor and about 15 years as a top executive. SVLS's device portfolio includes laser ablation firm CardioFocus, ventricular assist device company MicroMed, and diabetes product firm Insulet. The venture firm points out that LaViolette integrated more than 20 acquisitions during his time at Boston Scientific
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.